Glasgow prognostic score as a predictor of decompensation in patients with primary biliary cholangitis

Table 5 Association between Glasgow prognostic scores and decompensation risk in the sensitivity analysis after excluding patients with hypertension, atherosclerosis, or diabetes mellitus

Variable	Univariate analysis		Multivariate analysis
			Model A		Model B
	HR (95%CI)	P value	HR (95%CI)	P value	HR (95%CI)	P value
GPS	4.306 (3.230-5.740)	< 0.001	4.341 (3.246-5.805)	< 0.001	4.265 (3.118-5.834)	< 0.001
mGPS	3.602 (2.827-4.589)	< 0.001	3.547 (2.776-4.534)	< 0.001	3.400 (2.605-4.437)	< 0.001
hs-mGPS	3.464 (2.676-4.483)	< 0.001	3.463 (2.661-4.506)	< 0.001	3.423 (2.580-4.541)	< 0.001

Model A: Adjusted for age, sex, body mass index. Model B: Adjusted for all variables in model A plus total bilirubin, alanine aminotransferase, aspartate aminotransferase, alkaline phosphatase, gamma-glutamyl transferase, international normalized ratio, anti-mitochondrial antibody M2, anti-nuclear dot protein SP100 antibody, and anti-glycoprotein 210 antibody. CI: Confidence interval; GPS: Glasgow prognostic score; HR: Hazard ratio; hs-mGPS: High-sensitivity modified Glasgow prognostic score; mGPS: Modified Glasgow prognostic score.